Andrew Hillman's 2026 white paper on the regulatory and manufacturing standard for Wharton's jelly stem cell exosomes. We cover why the source tissue matters, why these products fall under Section 351(a), how a Type II Drug Master File works, and what donor testing, lot release, glass vials and cold chain shipping involve. FDA has not approved any exosome product. Hosted by Andrew Jonathan Hillman, Dallas, Texas. Permanent record (DOI): https://doi.org/10.5281/zenodo.20974697 Main site: https://andrew-hillman.com/ Publications: https://andrew-hillman.com/publications/ This episode is educational and is not legal or medical advice. Andrew Hillman is not an attorney. Narrated by an AI voice (synthetic narration). No real person's voice or likeness is used. Links and resources: Companion paper: https://andrew-hillman.com/publications/whartons-jelly-msc-exosomes-gold-standard/ Podcast home: https://andrew-hillman.com/podcast/ About the host: https://andrew-hillman.com/who-is-andrew-jonathan-hillman/ LinkedIn: https://www.linkedin.com/in/andrew-hillman-dallas The Hillman Letter on Substack: https://thehillmanletter.substack.com Apple Podcasts: https://podcasts.apple.com/us/podcast/the-hillman-letter-podcast/id6825615190 Spotify: https://open.spotify.com/show/2ZYUBaVrUxWDAhskCNTXzs YouTube playlist: https://www.youtube.com/playlist?list=PLElpO9MC9VC4 Academia.edu, SMU: https://smu.academia.edu/AndrewHillman ORCID: https://orcid.org/0009-0001-5396-321X Wikipedia: https://en.wikipedia.org/wiki/Andrew_Jonathan_Hillman Book a call: https://calendly.com/ajhusa Educational only. Not legal advice. Not an attorney.